Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2i vs DPP4i for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer
NCT07436663Phase 4Recruiting
- Sponsor
- Tanta University
- Start
- Feb 2026
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dapagliflozin, sitagliptin in Cardiotoxicity, sponsored by Tanta University. Started Feb 2026; status: recruiting.
02
Drugs
dapagliflozinsitagliptin
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on NCT07436663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07436663.